The AMR Accelerator Programme

The AMR Accelerator is an IMI Programme progressing the development of new medicines to treat or prevent resistant bacterial infections. We aim to deliver 10 preclinical or clinical candidates and 5 Phase II or III-ready assets.

Participants

479

M€ Budget

9

Projects

Programmes
in the Portfolio

Public Webinars

Public webinars

Tools and Resources

Tools and Resources

Project Publications

Publications

Project Portfolio

Project portfolio

Latest news from the AMR Accelerator Projects

29/10/24 – COMBINE ANNUAL MEETING 2024

14/02/2025 – RespiriNTM 2024 Consortium Meetings Recap

04/02/25 – PrIMAVeRa’s new publication on ‘Challenges in data sharing within the European community’

Protected: Yojana Gadiya: Title

14/01/25 – Join UNITE4TB Young Investigators – Call for 2025 Members

12/12/24 – ERA4TB researchers win prestigious Quality Innovation Award

10/12/24 – PrIMAVeRa spotlighted in the latest AMR Accelerator Newsletter

05/12/24 – UNITE4TB’s Journey: Interview with Project Lead, Derek Sloan

27/11/24 – UNITE4TB at Union Conference: Advancing TB Drug Development

Nasreen Hassoun-Kheir: A Doctor’s Mission to Stop Superbugs

22/11/24 – Research priorities for tackling AMR released during WAAW 2024

22/11/24 – RespiriTB launches Phase 1 trial of long-acting injectable bedaquiline (BDQ LAI).

Quentin J. Leclerc: Targeting Supercontactors for Safer Long-Term Care

20/11/24 – PrIMAVeRa 3rd Annual Meeting, Seville, 07-08 Nov 2024

18/11/24 – Advancing TB Treatment: An Update on the PARADIGM4TB Trial

06/11/24 – PrIMAVeRa Meeting with Vaccines Europe on AMR Reduction

25/10/24 – Managing Adverse Events in TB Care: Key Insights UNITE4TB Webinar

22/10/24 – BioVersys Joins RespiriNTM to Accelerate Development of the Broad-Spectrum Drug Candidates Against NTM Pulmonary Diseases

22/10/24 – ERA4TB researchers win prestigious Quality Innovation Award

14/10/24 – UNITE4TB Webinar: Intersecting the vulnerabilities of TB in migrants

02/10/24 – GNA NOW Annual & Expert Meeting

25/09/24 – The COMBINE Project Coordinator, Anders Karlén is Pharmacist of the Year 2024

24/09/2024 Sustaining European Antibiotics Through R&D Funding

23/09/24 – Sustainable Funding Needed to Preserve EU AMR & Tuberculosis R&D

23/09/24 – Sustainable funding required to protect early phase antibiotics R&D for TB and beyond.

The AMR Accelerator calls to action: European capacity for antibiotic R&D requires long-term funding

30/08/24 – ERA4TB to host workshop on TB Drug Development at The Union Conference 2024

22/08/24 – UNITE4TB webinar: Management of adverse events in TB care

13/08/24 – PrIMAVeRa project publishes on contact network dynamics to prevent pathogen transmission in hospitals

09/07/24 – UNITE4TB Completes Recruitment for DECISION Trial

25/06/24 – Key insights from PrIMAVeRa project year two progress review meeting

UNITE4TB Newsletter – June 2024

AMR Accelerator Newsletter – June 2024

28/05/24 – AB-Direct reaches its end

15/05/24 – PrIMAVeRa project partners present posters at ECCMID 2024

11/04/24 – RECORDING OF WEBINAR ON TPP FOR ANTIBIOTICS

09/04/24 – AMR ACCELERATOR CROSS-PROJECT MEETING 2024

08/03/24 – PrIMAVeRa participates in AMR Accelerator Cross-Project Meeting 2024

05/03/24 – TRIC-TB reaches its end

12/02/24 – ERA4TB researcher wins award for innovative research design

25/01/24 – Public launch of TB-Platform for the Aggregation of Preclinical Experiments Data (TB-APEX)

23/01/24 – GNA NOW consortium expands its scope to support the under-studied condition of severe diarrhoea

17/01/24 – ERA4TB launches new project video on progress

12/12/23 – BioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosis

Meindert Lamers: RespiriTB & RespiriNTM Projects

24/11/23 – PrIMAVeRa provides in-depth reports on current evidence base of burden of AMR in Europe

24/11/23 – PrIMAVeRa 2nd annual meeting successfully held in hybrid format in Utrecht on 15-16 November 2023

22/11/23 – UNITE4TB/PAN-TB Joint Satellite Session at the 2023 Union Conference

14/11/23 – Collaboration to improve the quality of in vivo antibiotics testing

08/11/23 – A new dawn in the fight against Tuberculosis: UNITE4TB announces start of clinical trials

22/06/23 – More than 100 ERA4TB members gather for 7th Consortium Meeting

19/06/23 – PrIMAVeRa Project Appoints Scientific Advisory Committee

11/05/23 – VOICES FROM THE AMR ACCELERATOR

10/05/23 – Impressions of the 2023 UNITE4TB Annual Meeting & Symposium

03/05/23 – A look back at the 2023 UNITE4TB Annual Consortium Meeting and Symposium

06/04/23 – PUTTING AMR ACCELERATOR SCIENCE ON THE COMMUNITY AGENDA

24/03/23 – UNITE4TB partakes in World TB Day 2023: Yes! We can end TB!

21/03/23 – ERA4TB members attend key meetings on Antimicrobial Resistance in Basel

16/02/23 – ERA4TB to partner with UNITE4TB for webinar focusing on community engagement in TB research

31/01/23 – BioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098

31/01/23 – Apply now to join the UNITE4TB Young Investigators Group

30/01/23 – ERA4TB partners gather for a face-to-face event in Paris for 6th Consortium Meeting

23/01/23 – ERA4TB marks its halfway point with 6th Consortium meeting in Paris

RespiriTB – Boosting innate immunity to combat Mycobacterium avium infection

14/12/22 – UNITE4TB 2022 highlights

12/12/22 – The power of words: the importance of appropriate language use in TB communications from UNITE4TB

30/11/22 – PPrIMAVeRa 1st annual meeting successfully held in a hybrid event in Verona

INTERVIEW WITH IHI EXECUTIVE DIRECTOR AD INTERIM

16/11/22 – Meaningful engagement of the community in TB Research & Development: Best practice initiative from UNITE4TB

25/10/22 – New publication from GNA NOW Consortium published by the American Society for Microbiology

17/10/22 – ERA4TB Webinar on Challenges of tuberculosis (TB) drug development and access – clinical, regulatory and HTA perspectives

21/09/22 – ERA4TB participates in the #WorldEBHCDay campaign, ‘Partnerships for Purpose’

19/09/22 – UNITE4TB Clinical trial preparations in Vietnam

19/09/22 – UNITE4TB Exploring synergies and collaborations

19/09/22 – The UNITE4TB Community Advisory Group: Voice of the TB community

19/09/22 – Year-1 highlights from the UNITE4TB project leads

21/06/22 – BioVersys successfully completes Phase I clinical trials of BVL-GSK098

08/06/22 – Positive results for preclinical development of the first-in-class antibiotics NOSO-502

18/05/22 – UNITE4TB 2022 Annual Meeting

04/05/22 – Expert interview: Microbiologists on tuberculosis diagnostics

INTERVIEW WITH PRIMAVERA PROJECT COORDINATOR

06/04/22 – 3rd AMR Accelerator cross-project meeting held as in-person event

25/02/22 – UNITE4TB Community Advisory Group holds inaugural meeting

03/02/22 – PrIMAVeRa WP2 workshop, virtually held on 27-28 January 2022

03/12/21 – ERA4TB schedules the 4th consortium meeting on 27th and 28th of January 2022

01/12/21 – PrIMAVeRa kick-off meeting successfully marks the official project launch

INTERVIEW WITH ALMARI CONRADIE FROM ERA4TB PROJECT

22/11/21 – Antimicrobial Resistance: the silent pandemic

18/11/21 – Tuberculosis projects represent the biggest ever funding effort to combat the disease

INTERVIEW WITH UNITE4TB PROJECT COORDINATOR

INTERVIEW WITH IMI EXECUTIVE DIRECTOR

15/07/21 – Launch of UNITE4TB partnership

06/07/21 – BioVersys pipeline presentations at ECCMID July 9-12, 2021

10/05/21 – Open Call: Apply now to join the GNA NOW Consortium

INTERVIEW WITH COMBINE PROJECT COORDINATOR

INTERVIEW WITH GNA NOW PROJECT LEADER

25/03/21 – Tackling antibiotic resistance together

02/21 -Launch of AB-Direct Phase 1 study

12/01/21 – BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BVL-GSK098

24/06/20 – Successful First Annual Meeting for IMI project GNA NOW

23/06/20 – BioVersys receives QIDP designation for BVL-GSK098 and ETH

11/03/20 – COMBINE Call for preclinical and clinical data sets

29/01/20 – ERA4TB, the new IMI project to accelerate the fight against tuberculosis

© Daniela Beckmann

03/12/19 – IMI project COMBINE launched

Learn more about the AMR Accelerator Projects

7 participants
> 3.7 M€ budget
4 years & 3 months. Started 1 July 2019

Antibiotic distribution and recovery in tissue

Circle_ABDirect

11 participants
25 M€ budget
6 years. Started 1 Nov 2019

Coordination and support across the AMR Accelerator. Research to strengthen the scientific basis in the AMR field.

Circle_COMBINE

32 participants
> 207 M€ budget
6 years. Started 1 Jan 2020

Development of anti-TB drug combinations

Circle_ERA4TB

12 participants
21.6 M€ budget
6 years. Started 1 July 2019

New antibiotics to treat Gram-negative infections

Circle_GNANOW

18 participants
9.25 M€ budget
5 years. Started 1 November 2021

Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance

Asset 1

9 participants
> 8 M€ budget
6 years. Started 1 May 2019

Novel assets for non-tuberculous mycobacteria

Circle_RespiriNTM

9 participants
> 9.9 M€ budget
6 years. Started 1 May 2019

New assets for multidrug-resistant tuberculosis

Circle_RespiriTB

2 participants
> 8.3 M€ budget
4 years & 10 months. Started 1 May 2019

Defining a new place for Ethionamide in 1st-line TB treatments

Circle_TricTB-1

29 participants
185 M€ budget
7 years. Started 1 June 2021

Accelerating the development of new treatment regimens for tuberculosis

Stay up-to-date with the AMR Accelerator!

Follow us:

The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976 I 101007873 I 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee. UNITE4TB receives additional support from Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

https://www.imi.europa.eu/